Drug intelligence / Profile preview

lactobacillus casei + lactobacillus rhamnosus lcr35

Development stage
Unknown
Lead developer
Biose Industrie
Modality
Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
Administration
Oral, Vaginal
01

Overview

Lactobacillus casei + Lactobacillus rhamnosus Lcr35 is a combination of probiotic bacterial strains intended to support or restore a healthy microbiome. [10] The combination is used for both gastrointestinal and gynecological health. [2, 6] The Lcr35 strain, specifically Lacticaseibacillus rhamnosus Lcr35, is a well-documented, patented probiotic developed by Biose Industrie. [2, 11] Its original name was Lactobacillus casei rhamnosus 35, which explains the potential naming confusion. [23] Probiotics like these function by competing with pathogenic microorganisms, adhering to epithelial cells to form a protective barrier, and producing antimicrobial substances like lactic acid, which helps maintain a healthy pH. [19] They also modulate the host's immune system. [8, 16] The Lcr35 strain has demonstrated an ability to inhibit pathogens such as *Candida albicans*, *Gardnerella vaginalis*, and pathogenic *Escherichia coli*. [2, 6] This combination is typically available in oral capsules for gut health or vaginal tablets for gynecological applications. [10, 17]

Brand names
Gynophilus
Other names
Lcr Regenerans
02

Targets

TLR2 (Toll-like Receptor 2)

Beyond the preview

Go deeper on lactobacillus casei + lactobacillus rhamnosus lcr35.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on lactobacillus casei + lactobacillus rhamnosus lcr35.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call